Is Tirzepatide the Same as Ozempic? Short Answer: No, They Are Different Drugs

Key Takeaways

• Tirzepatide and Ozempic are not the same drug. Ozempic contains semaglutide. Tirzepatide is sold as Mounjaro (for type 2 diabetes) and Zepbound (for weight loss).
• Semaglutide acts on one hormone receptor (GLP-1). Tirzepatide acts on two (GLP-1 and GIP), which is why head-to-head trial data shows it produces larger average weight loss.
• In the SURMOUNT-1 trial, tirzepatide 15 mg produced about 20.9% mean body-weight loss at 72 weeks. In STEP 1, semaglutide 2.4 mg produced about 14.9% at 68 weeks.
• They are not interchangeable. Doses, titration schedules, side-effect profiles, and pen devices differ. Switching between them requires a new prescription and usually a new starting dose.
• Compounded semaglutide and compounded tirzepatide are also distinct. They are not FDA-approved and are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound.

Direct answer (40-60 words)

No. Tirzepatide and Ozempic are different medications. Ozempic's active ingredient is semaglutide, a single GLP-1 receptor agonist. Tirzepatide is a separate molecule sold under the brand names Mounjaro (for diabetes) and Zepbound (for obesity). Tirzepatide acts on two receptors, GLP-1 and GIP, which is why average weight loss in trials is higher.

Table of contents

1. The 30-second answer
2. What is tirzepatide?
3. What is Ozempic?
4. Side-by-side comparison table
5. How the receptor difference changes the effect
6. Weight-loss data: SURMOUNT-1 vs STEP 1
7. A1C reduction: SURPASS-2 head-to-head
8. Side-effect profiles compared
9. Dosing and titration: not interchangeable
10. Switching between tirzepatide and semaglutide
11. Cost and availability
12. Compounded versions of each
13. FAQ

What is tirzepatide?

Tirzepatide is a once-weekly injectable peptide developed by Eli Lilly. It activates two gut-hormone receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). It received FDA approval as Mounjaro for type 2 diabetes in May 2022 and as Zepbound for chronic weight management in November 2023.

The molecule is a 39-amino-acid synthetic peptide. It binds the GIP receptor with about the same affinity as natural GIP, and binds the GLP-1 receptor with somewhat lower affinity than natural GLP-1, but the half-life is extended to roughly 5 days through a fatty-acid chain that helps it stick to albumin in the bloodstream (Coskun et al., Mol Metab 2018). That long half-life is what allows once-weekly dosing.

Tirzepatide is dosed in milligrams: 2.5, 5, 7.5, 10, 12.5, and 15 mg. It comes in single-use prefilled pens for both Mounjaro and Zepbound, with the same drug substance in both products.

What is Ozempic?

Ozempic is the brand name Novo Nordisk uses for semaglutide injection at doses of 0.25, 0.5, 1, and 2 mg, FDA-approved for type 2 diabetes since December 2017. Semaglutide is a single-receptor GLP-1 agonist. The same molecule is sold as Wegovy at higher doses (up to 2.4 mg weekly) for chronic weight management, and as Rybelsus in oral tablet form for diabetes.

Semaglutide is a 31-amino-acid synthetic peptide derived from human GLP-1 with two amino acid substitutions and a fatty-acid side chain that extends its half-life to about 7 days (Lau et al., J Med Chem 2015). One molecule, three brand names, three FDA approvals, three pricing structures.

So when somebody asks if "Ozempic" is the same as "tirzepatide," the answer involves both a brand-name question (Ozempic vs Mounjaro/Zepbound) and a molecule question (semaglutide vs tirzepatide).

Side-by-side comparison table

How the receptor difference changes the effect

The mechanistic difference between the two drugs is not academic. The GIP receptor does several things that the GLP-1 receptor does not.

GLP-1 activation slows gastric emptying, increases insulin secretion in response to glucose, suppresses glucagon, and reduces appetite signaling in the hypothalamus. Semaglutide does all four of those things.

GIP activation, when added on top of GLP-1, contributes additional insulin secretion at high glucose, improves lipid handling, increases adipose-tissue insulin sensitivity, and may centrally enhance satiety in ways that complement GLP-1 (Samms et al., Trends Endocrinol Metab 2020). The net result in animal and human studies is greater weight loss and greater glucose lowering at clinically tolerated doses.

In plain terms: tirzepatide is hitting two satiety and glucose-control levers at once, while semaglutide is hitting one. That is the core reason head-to-head data favors tirzepatide on weight and A1C endpoints.

Weight-loss data: SURMOUNT-1 vs STEP 1

The primary weight-loss trials for each drug used similar designs in similar populations. They were not directly compared in the same study, but the numbers are close enough that cross-trial comparison is informative.

SURMOUNT-1 (Jastreboff et al., NEJM 2022). 2,539 adults with obesity or overweight plus a weight-related condition, no diabetes. 72 weeks. Tirzepatide 15 mg: -20.9% body weight. Tirzepatide 10 mg: -19.5%. Tirzepatide 5 mg: -15.0%. Placebo: -3.1%.

STEP 1 (Wilding et al., NEJM 2021). 1,961 adults with obesity or overweight plus a weight-related condition, no diabetes. 68 weeks. Semaglutide 2.4 mg: -14.9% body weight. Placebo: -2.4%.

So at the highest approved dose of each drug, tirzepatide produces about 6 percentage points more average weight loss. That translates roughly to an additional 12 to 15 pounds for someone who weighs 200 pounds at baseline.

The variance between individuals is wide. Some patients lose more on semaglutide than the trial average for tirzepatide. Picking a drug based on average data alone misses the individual response question, which can only be answered by trying one.

A1C reduction: SURPASS-2 head-to-head

The one direct head-to-head trial of the two molecules was SURPASS-2 (Frias et al., NEJM 2021). 1,879 adults with type 2 diabetes on metformin were randomized to tirzepatide 5, 10, or 15 mg or to semaglutide 1 mg, all weekly, for 40 weeks.

Results:

Tirzepatide produced a larger A1C drop and roughly 2 to 6 kg more weight loss across all three doses. Note that the semaglutide arm used 1 mg, not the 2 mg high-dose Ozempic that became available later. A 2 mg head-to-head against tirzepatide has not been published.

Side-effect profiles compared

Both drugs share the GLP-1 class side-effect profile: nausea, vomiting, diarrhea, constipation, and abdominal pain are the most common. These are usually worst during titration and improve as the body adapts.

Comparative rates from SURPASS-2:

Tirzepatide's GI rates are modestly higher at the 15 mg dose. At lower equivalent doses (tirzepatide 5 mg vs semaglutide 1 mg), the rates are similar. Both drugs carry warnings for pancreatitis, gallbladder disease, and a boxed warning for thyroid C-cell tumors based on rodent data. The thyroid risk has not been confirmed in humans (FDA Prescribing Information, both products, 2024).

Dosing and titration: not interchangeable

Tirzepatide and semaglutide use different dose ladders. You cannot translate one to the other directly.

Semaglutide titration (Ozempic for diabetes): 0.25 mg/week for 4 weeks, then 0.5 mg for at least 4 weeks, then optionally 1 mg, then optionally 2 mg.

Tirzepatide titration: 2.5 mg/week for 4 weeks, then 5 mg for at least 4 weeks, then 7.5, 10, 12.5, and 15 mg in 4-week increments as needed.

There is no clean dose-equivalency table. Rough clinical heuristics that providers use, drawn from SURPASS-2 and clinical experience:

• Semaglutide 0.5 mg ≈ tirzepatide 2.5 to 5 mg (entry doses)
• Semaglutide 1 mg ≈ tirzepatide 5 to 7.5 mg
• Semaglutide 2 mg ≈ tirzepatide 7.5 to 10 mg
• No semaglutide equivalent for tirzepatide 12.5 or 15 mg

These are approximate and based on average response. Individual response varies widely.

Switching between tirzepatide and semaglutide

Patients sometimes switch between the two drugs because of side effects, cost, supply, or efficacy. The general clinical pattern:

Going from semaglutide to tirzepatide. Most providers start tirzepatide at 2.5 mg, the standard starting dose, regardless of the prior semaglutide dose. Some providers will start at 5 mg if the patient was tolerating 1 to 2 mg of semaglutide. There is a 1 to 2 week wash-out from the last semaglutide dose before the first tirzepatide dose, because both drugs slow gastric emptying and stacking them increases nausea risk.

Going from tirzepatide to semaglutide. Standard practice is to start semaglutide at 0.25 mg, the labeled starting dose. Some providers start at 0.5 mg if the patient was on tirzepatide 5 mg or higher and tolerating well. Wash-out is similar.

Switching mid-treatment without titration is not recommended. The receptor profiles and dose ranges are different enough that the body needs time to adapt.

Cost and availability

Brand-name pricing as of Q1 2026 is similar between the two. Ozempic cash price runs about $940 to $1,150 per month. Mounjaro and Zepbound cash prices run about $1,000 to $1,250 per month. With commercial insurance, copays vary by formulary tier from $25 to $500. With manufacturer savings cards, eligible commercially insured patients can pay as low as $25 per fill.

Coverage policies differ between the brands. Many plans put one drug on a preferred tier and the other on a higher tier, which can swing out-of-pocket cost by hundreds of dollars per month. Checking your plan's formulary before deciding is the only reliable way to know what you'll actually pay.

For supply: both drugs were on the FDA shortage list at various points in 2022 to 2024. As of late 2024, the FDA declared semaglutide and tirzepatide shortages resolved. Compounded versions remain available through 503A pharmacies for patients with documented clinical need or specific dose requirements.

For more on out-of-pocket pricing scenarios, see /articles/answers-hub/ozempic-cost-at-walmart-with-insurance-what-youll-actually-pay.

Compounded versions of each

Compounded semaglutide and compounded tirzepatide are sometimes confused with the brand-name products. They are not the same.

Compounded semaglutide is prepared by a state-licensed compounding pharmacy in response to an individual prescription. It contains the same active ingredient (semaglutide) as Ozempic, Wegovy, and Rybelsus, but it is not FDA-approved. It is typically supplied in a vial with a U-100 insulin syringe rather than a pre-filled pen. It is not interchangeable with brand-name semaglutide products.

Compounded tirzepatide is the same situation: same molecule as Mounjaro and Zepbound, prepared by a 503A or 503B pharmacy, not FDA-approved, supplied in a vial. Not interchangeable with brand-name tirzepatide products.

The clinical effect of well-prepared compounded products is generally similar to the brand-name versions at equivalent doses, but quality, sterility, and dose accuracy depend on the specific pharmacy. The FDA does not test compounded products for potency or contamination.

For more on the compounded category, see /articles/answers-hub/why-is-my-compounded-semaglutide-red-understanding-the-color-variations.

FAQ

Is tirzepatide the same as Ozempic? No. Ozempic's active ingredient is semaglutide, which acts on a single receptor (GLP-1). Tirzepatide is a different molecule that acts on two receptors (GLP-1 and GIP) and is sold as Mounjaro for diabetes and Zepbound for weight loss.

Is tirzepatide just a stronger version of semaglutide? No. They are different molecules with different receptor profiles. Tirzepatide is not "stronger semaglutide." It does more things mechanistically because it activates the GIP receptor in addition to GLP-1.

Can I switch from Ozempic to tirzepatide? Yes, with provider guidance. Most patients restart at the standard tirzepatide starting dose of 2.5 mg/week, regardless of prior semaglutide dose. A 1 to 2 week wash-out between the last semaglutide dose and the first tirzepatide dose is typical.

Will tirzepatide work better for me than Ozempic? On average, yes, for both weight loss and A1C reduction. Individual response varies widely. Some patients respond better to semaglutide than to tirzepatide. The only way to know your individual response is to try one.

Why is tirzepatide more effective in trials? Tirzepatide activates both GLP-1 and GIP receptors. This dual mechanism produces greater satiety, larger insulin response to meals, and improved lipid handling compared to GLP-1 activation alone.

Is Mounjaro the same as Zepbound? Yes, the active ingredient and pen device are identical. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is FDA-approved for chronic weight management. Eli Lilly sells the same drug under two brand names because the FDA approval pathway requires separate trials for separate indications.

Is Wegovy the same as Ozempic? Wegovy and Ozempic both contain semaglutide. Wegovy goes up to 2.4 mg weekly and is FDA-approved for chronic weight management. Ozempic goes up to 2 mg weekly and is FDA-approved for type 2 diabetes. Same molecule, different indications, slightly different dose ranges.

Are tirzepatide and semaglutide both peptides? Yes. Both are synthetic peptides, meaning they are short chains of amino acids with structural similarity to natural human gut hormones. Both are modified to extend their half-life to allow once-weekly dosing.

Do tirzepatide and Ozempic have the same side effects? The categories are the same: nausea, vomiting, diarrhea, constipation, abdominal pain. Rates are slightly higher for tirzepatide at the highest doses. Both carry warnings for pancreatitis, gallbladder disease, and (boxed) thyroid C-cell tumor risk based on rodent studies.

Can I take tirzepatide and Ozempic together? No. Combining two GLP-1 class agents is not recommended. The side-effect risk multiplies and there is no proven additional benefit. Patients switching between them should fully wash out one before starting the other.

Is tirzepatide approved for weight loss? Yes, as Zepbound, since November 2023. Mounjaro contains the same drug but is FDA-approved only for type 2 diabetes. Insurance coverage differs between the two brand names.

Is Ozempic approved for weight loss? No. Ozempic is FDA-approved only for type 2 diabetes. Semaglutide for weight loss is sold as Wegovy. Off-label prescribing of Ozempic for weight loss is legal but is often denied by insurance.

Sources

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216.
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002.
3. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
4. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist, for the treatment of type 2 diabetes mellitus. Mol Metab. 2018;18:3-14.
5. Lau J, Bloch P, Schaffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370-7380.
6. Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab. 2020;31(6):410-421.
7. Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7). Lancet Diabetes Endocrinol. 2018;6(4):275-286.
8. Eli Lilly. Mounjaro (tirzepatide) Prescribing Information. Revised 2024.
9. Eli Lilly. Zepbound (tirzepatide) Prescribing Information. Revised 2024.
10. Novo Nordisk. Ozempic (semaglutide) Prescribing Information. Revised 2024.
11. Novo Nordisk. Wegovy (semaglutide) Prescribing Information. Revised 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.